Strategy
Key Achievements
History
Team
Management
Board of Directors
Advisory Boards
Wounds
Chronic Wounds
KUR-211
Acute Wounds
KUR-213
Burns
KUR-212
Tissue Sealants
KUR-023
Trauma
Fracture Repair
KUR-111
KUR-113
KUR-411
KUR-024
Solitary Bone Cysts
KUR-112
Undisclosed Indication
KUR-114
Spine
VCF
KUR-021
DDD
KUR-521
Undisclosed Indication
KUR-115
KUR-116
Biomolecules Engineering
Fibrin Matrix
Synthetic Matrix
Patents
Publications
Business Development
Contact
Shareholders
Investors
Home
·
News
·
Jobs
·
Contact
News
June 2010: Kuros completes recruitment in Phase IIb study of KUR-113
(auf Deutsch)
Zurich, Switzerland, 2nd June 2010 - Kuros Biosurgery AG, a biotechnology company focused on the...
March 2010: KUR-111 meets primary efficacy endpoint in Phase IIb study
(auf Deutsch)
Zurich, Switzerland, 15th March 2010 - Kuros Biosurgery AG announced today the results of a...
August 2009: Kuros announces encouraging Phase IIa data with KUR-212 in patients with burns requiring mesh grafting
(auf Deutsch)
Zurich, Switzerland, 12h August 2009 - Kuros Biosurgery AG announced today the final results of...
Print
Disclaimer